

- *HIV prevention services:* Voluntary medical male circumcision; Cervical cancer prevention and treatment; Gender based violence Prevention and response; Condom programming; Pre-exposure prophylaxis; Elimination of mother-to-child transmission; Support for Key and vulnerable populations and Orphans and vulnerable children;

- HIV treatment and support services for all age groups across the care continuum from case finding to viral load suppression. Support will include: Prevention and management of opportunistic infections and advanced HIV disease, as well as non-communicable diseases (including support for mental health);

- Health system strengthening including support to financial and administrative management systems, internal controls, human resources for health, health information systems, supply chain/commodities management, laboratory services, and continuous quality improvement.

The Provincial Health Offices are the single entities eligible for this award since they are the sole government institutions with the mandate to support health service delivery through capacity building, systems strengthening, and oversight for HIV program implementation for the population of Zambia per the National Health Policy and Zambian National Health Strategic Plan.

### Summary of the Award

*Recipient:* Southern Provincial Health Office; Lusaka Provincial Health Office; Western Provincial Health Office; and Eastern Provincial Health Office in Zambia.

*Purpose of the Award:* The purpose of this award is to provide PHOs with CDC technical assistance and financial support to maintain and sustain the province's overall leadership and oversight for implementing high-impact HIV combination prevention, treatment, and support services, including clinical, surveillance, and laboratory services as well as to identify and mitigate emerging disease threats for PLHIV. Specifically, it will serve to strengthen capacity development activities, while providing optimal health systems strengthening in support of continued and sustainable HIV epidemic control in Zambia.

*Amount of Award:* The approximate year 1 funding amount in Federal Fiscal Year (FFY) 2022 funds will be, subject to the availability of funds:

- Southern Provincial Health Office (SPHO): Anticipated Year 1 Funding Amount is \$14,500,000

- Lusaka Provincial Health Office (LPHO): Anticipated Year 1 Funding Amount is \$19,000,000
- Western Provincial Health Office (WPHO): Anticipated Year 1 Funding Amount is \$12,000,000
- Eastern Provincial Health Office (EPHO): Anticipated Year 1 Funding Amount is \$12,000,000;

Funding amounts for years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

*Period of Performance:* September 30, 2022, through September 29, 2027.

Dated: March 2, 2022.

**Terrance Perry,**

*Chief Grants Management Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022–04827 Filed 3–7–22; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Award of a Single-Source Cooperative Agreement To Fund the National AIDS Control Committee (NACC), Cameroon

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$3,000,000 for Year 1 of funding to the National AIDS Control Committee (NACC), Cameroon. The award will strengthen national policies, build capacity, and define high-level high-impact interventions and key strategies for HIV/TB prevention, treatment and care in Cameroon. Funding amounts for years 2–5 will be set at continuation.

**DATES:** The period for this award will be September 30, 2022, through September 29, 2027.

**FOR FURTHER INFORMATION CONTACT:** Lisa Esapa, Center for Global Health, Centers for Disease Control and Prevention, Standard Chartered Bank Building, Hippodrome, Telephone: 800–232–6348, Email: [hww5@cdc.gov](mailto:hww5@cdc.gov).

**SUPPLEMENTARY INFORMATION:** The single-source award will implement HIV prevention, care and treatment in Cameroon through activities, including:

Developing and implementing policies and strategies to optimize case finding, HIV treatment and retention, viral load coverage and suppression, and building workforce capacity to improve uptake and quality of these HIV/TB services; and enhancing the implementation of evidence-based prevention interventions for KPs (key populations) /PPs (priority populations) /GP (general populations). Implementation of this award will enhance scale up of services and improve quality of diagnostics, treatment, management, and clinical outcomes for HIV and TB infections in Cameroon. This award will build upon CDC's initial successful partnerships to address these challenges and gaps and complement Global Fund efforts. NACC is in a unique position to conduct this work, as it is the organization mandated by the Government of Cameroon to coordinate HIV/AIDS activities in Cameroon. NACC is essential to building effective national-level coordination in HIV programs, as mandated in the 2000–2005 and 2006–2010 National HIV/AIDS Strategic Plans. The mission of NACC is to coordinate a comprehensive and effective multi-sector and decentralized national response to HIV/AIDS, including coordination and support to the health sector response.

### Summary of the Award

*Recipient:* National AIDS Control Committee (NACC), Cameroon.

*Purpose of the Award:* The purpose of this award is to strengthen national policies and define high-level high-impact interventions and key strategies for HIV/TB prevention, treatment and care; improve knowledge and prevent high risk behaviors associated with STIs/HIV; monitor and ensure the elimination of user fees for all HIV/TB services; develop national quality improvement policy and setup CQI management system; provide technical capacity to generate quality data; reduce HIV/TB related morbidity and mortality; and provide capacity to coordinate and monitor the national HIV response in Cameroon.

*Amount of Award:* The approximate year 1 funding amount will be \$ 3,000,000 in Federal Fiscal Year (FFY) 2022 funds, subject to the availability of funds. Funding amounts years 2–5 will be set at continuation.

*Authority:* This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

*Period of Performance:* September 30, 2022, through September 29, 2027.

Dated: March 2, 2022.

**Terrance Perry,**

*Chief Grants Management Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2022-04788 Filed 3-7-22; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Prospective Grant of an Exclusive Patent License: NCGC00413972 and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the **SUPPLEMENTARY INFORMATION** section of this notice to Macala Bio, Inc. located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 23, 2022 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Eric Cheng, Ph.D., Licensing and Patenting Manager at (240)-276-5530 or [eric.cheng2@nih.gov](mailto:eric.cheng2@nih.gov).

#### **SUPPLEMENTARY INFORMATION:**

##### **Intellectual Property**

United States Provisional Patent Application No. 62/950,488, filed 19 December 2019 and entitled "CD206 Modulators Their Use And Methods For Preparation" [HHS Reference No. E-105-2019/0-US-01];

PCT Patent Application PCT/US2020/065238, filed 16 December 2020 and entitled "CD206 Modulators Their Use And Methods For Preparation" [HHS Reference No. E-105-2019-0-PCT-02].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to: NCGC00413972 and its related analogs consisting of an imidazo-pyrazine scaffold core for the treatment or prevention of cancers expressing the mannose receptor CD206, including both solid tumors and hematological malignancies.

This technology discloses immunotherapy drugs, and to compounds that modulate CD206 as well as their use and methods for preparation.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 2, 2022.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2022-04829 Filed 3-7-22; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Submission for OMB Review; 30-Day Comment Request Generic Clearance for National Cancer Institute (NCI) NCI Resources, Software and Data Sharing Forms (National Cancer Institute)**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has

submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function.

**FOR FURTHER INFORMATION CONTACT:** To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Diane Kreinbrink, Office of Management Policy and Compliance, National Cancer Institute, 9609 Medical Center Drive, Rockville, Maryland, 208 or call non-toll-free number (240) 276-7283 or email your request, including your address to: [diane.kreinbrink@nih.gov](mailto:diane.kreinbrink@nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**SUPPLEMENTARY INFORMATION:** This proposed information collection was previously published in the **Federal Register** on December 20, 2021 (Vol. 86 FR 71901) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health (NIH), may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid Office of Management and Budget (OMB) control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, NIH has submitted to OMB a request for review and approval of the information collection listed below.

**Proposed Collection:** Generic Clearance for NCI Resources, Software and Data Sharing Forms, 0925—NEW, Expiration Date xx/xx/xxxx, NCI, NIH.

**Need and Use of Information Collection:** In preparation for dissemination and sharing of data sets, forms requesting or applying for access, upload, share, and store data will be needed. The purpose of data sharing